811 Ranolazine reduces Trastuzumab toxicity in vitro and in vivo, when it is administered after anticancer treatment
Nicola Maurea(Cancer Institute (WIA)), Michelino De Laurentiis(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Giovanna Piscopo(University of Cagliari), Carmela Coppola, Immacolata Capasso(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Elisabetta Esposito(University of Ferrara), Gennaro Riccio(Sapienza University of Rome), F. Galletta(University of Cagliari), Claudia De Lorenzo(Istituto Nazionale di Fisica Nucleare, Sezione di Napoli), C. Arra
Cited by 0
Related Papers
Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial
|The Lancet Oncology|2018|1k
Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer
|Annals of Oncology|2021|743
Fish Waste: From Problem to Valuable Resource
|Marine Drugs|2021|568
The SGLT-2 inhibitor empagliflozin improves myocardial strain, reduces cardiac fibrosis and pro-inflammatory cytokines in non-diabetic mice treated with doxorubicin
|Cardiovascular Diabetology|2021|368
Androgen receptor in triple negative breast cancer: A potential target for the targetless subtype
|Cancer Treatment Reviews|2018|282